| Name | Title | Contact Details |
|---|
Lombard Medical Technologies (LMT) develops, manufactures and markets stent grafts for the treatment of abdominal and thoracic aortic aneurysms, endovascular stapling devices for the fixation of stent grafts and percutaneous heart valves, and develops drug delivery coatings. The Company was established in July 2000 and currently employs over 100 people at Didcot, Sheffield and Ayrshire in the UK and in the USA. The Company also has trade investments in an emerging medical device company. Lombard Medical Technologies PLC is listed on the London Stock Exchange (AIM) under the symbol LMT.
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
G Hartzell and Son is a Concord, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jeen International Corp is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Merz Aesthetics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.